Cronos Group (CRON) Q2 2026 Earnings: $827M Cash, Altria's 41% Stake, Israel Duty Risk
Listen to this report
The Hook
Cronos Group $CRON just posted the best quarter in its history. Net revenue of 53.0 million dollars, up 58 percent year over year. Gross margin of 54 percent, up eleven points. Its first quarter of positive GAAP operating income in this cycle, at 7.4 million dollars. Analysts had modeled 44.73 million dollars of revenue and one cent of earnings; Cronos delivered nine cents, and the shares rose 13.2 percent in premarket trading on the release, per Investing.com.
And in that same record quarter, the interest Cronos earned on its own cash pile, 8.8 million dollars, was still larger than the 7.4 million dollars its cannabis business earned from operating. For the first six months of 2026 it is not close: interest income of 17.7 million dollars against operating income of 5.6 million dollars, a ratio of more than three to one. On management's own preferred measure, Adjusted EBITDA of 18.2 million dollars for the half, the entire cannabis operation earned 18.2 million while the treasury earned 17.7 million. Ninety seven cents of interest for every dollar the business made.
Cronos is a cannabis company sitting on 827.0 million dollars of cash, short-term investments and interest-bearing deposits, against a market capitalization of roughly 1.16 billion dollars at the August 14, 2026 close of 3.14 dollars. You pay 3.14 dollars a share, and 2.23 dollars of that is money in Canadian guaranteed investment certificates.
Company Snapshot
Cronos Group is a Canadian cannabis producer, incorporated in British Columbia, headquartered in Stayner, Ontario, listed on both the Toronto Stock Exchange and the Nasdaq. It sells under four brands: Spinach, PEACE NATURALS, LIT and Lord Jones. It reports as a single segment covering Canada and Israel, and it exports into Germany and other markets. Its principal cannabis supply comes from Cronos GrowCo, in which it holds a 50 percent equity interest and, since July 2024, majority control of the board, which is why GrowCo is consolidated and a 48.8 million dollar non-controlling interest sits in equity.
One thing Cronos does not do is touch a cannabis plant in the United States. That matters for how you read this company against its US peers. Section 280E of the Internal Revenue Code, the provision that bars US cannabis operators from deducting ordinary business expenses and drives their effective tax rates to 50 percent and beyond, does not apply to Cronos. The company's tax line is small for an entirely different reason: it has accumulated losses to shelter income. Its income tax provision was 51 thousand dollars for the quarter and 2.5 million dollars for the half, and the MD&A attributes the increase to "decreased net operating loss utilization." Note the distinction the numbers force: that 2.5 million dollars is tax expense accrued on the income statement. Cash income taxes paid in the six months were 14 thousand dollars.
This analysis is built on the Form 10-Q filed August 6, 2026 for the quarter ended June 30, 2026, accession 0001656472-26-000051, with prior-period comparisons pulled from the FY2025 Form 10-K and the Q1 2026 Form 10-Q.
The Financial Story
Start with what genuinely improved, because it did. Cronos grew through the cannabis bust rather than shrinking through it. Net revenue went from 64.6 million dollars in 2021 to 146.6 million dollars in 2025, and the first half of 2026 alone did 98.2 million. The growth this quarter came from the highest-margin places: Israel up 60 percent to 15.0 million dollars, other countries including Germany up 88 percent to 9.3 million, Canada up 50 percent to 28.7 million. Israel and export sales carry no Canadian excise tax, and the filing is explicit that this mix shift is what drove margin, not price discipline alone. Excise took 17.6 million dollars off gross revenue in the quarter, roughly 25 percent of the 70.6 million dollars billed.
| Metric (USD) | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Net revenue | 53.0M | 33.5M | +58% |
| Gross profit | 28.5M | 14.5M | +96% |
| Gross margin | 54% | 43% | +11 pp |
| Operating income | 7.4M | (5.3M) | +12.7M |
| Interest income, net | 8.8M | 9.0M | -2% |
| Adjusted EBITDA | 13.1M | 1.7M | +11.4M |
| Net income attributable | 32.1M | (39.7M) | +71.8M |
Now read the second column of that table against the fifth. Interest income barely moved. It is the one line on the income statement that does not care whether Cronos sells a gram of cannabis, and it went down, by 2 percent in the quarter and 5 percent for the half, because Canadian rates fell. It is also the line that has been carrying the company. In Q1 2026, three months before this celebrated quarter, Cronos ran an operating loss of 1.8 million dollars and still reported 13.8 million dollars of net income, because interest income was 8.9 million and a currency gain was 13.7 million.
Which brings up the largest number in the reported profit, and it is not interest and it is not cannabis. It is foreign exchange.
| Where the first-half pre-tax income came from (USD) | Amount | Share |
|---|---|---|
| Operating income (the cannabis business) | 5.6M | 10% |
| Interest income, net (the cash pile) | 17.7M | 33% |
| Foreign currency gain, non-cash | 33.9M | 63% |
| Loss on revaluation of financial instruments | (3.1M) | -6% |
| Other, net of small items | (0.2M) | 0% |
| Income before income taxes | 53.9M | 100% |
Sixty three percent of Cronos's first-half pre-tax income is an unrealized currency translation gain. It is non-cash, it is added straight back in management's own Adjusted EBITDA reconciliation, and it reverses. In the same six months of 2025 that identical line was a 38.0 million dollar loss, which is the entire reason Cronos reported a 33.6 million dollar net loss last year on an operating loss of only 9.4 million. The reported earnings of this company are, in any given quarter, mostly a bet on the Canadian dollar.
Cash flow is the cleaner signal, and it is genuinely better: 34.9 million dollars of operating cash flow in the half against 0.7 million a year ago. But even there, the supplemental disclosure shows 21.8 million dollars of that was cash interest received. Sixty three percent of operating cash flow was the bank paying Cronos.
The last thing to correct is the idea that the cash is running down. It is not. The 41 percent collapse in the "cash and cash equivalents" line, from 791.8 million dollars to 467.0 million, is a reclassification, not a burn. Cronos moved 330.0 million dollars into short-term guaranteed investment certificates and 30.0 million into a non-current interest-bearing deposit. The filing prints the combined line itself: total cash, short-term investments and non-current interest-bearing deposits went from 831.8 million dollars to 827.0 million. Down 4.8 million dollars, or 1 percent, in six months, while funding 32.9 million of buybacks, 3.6 million of capex and a 3.7 million distribution to the GrowCo minority. Total liabilities are 62.4 million dollars. There is no debt.
Catalyst Scenarios: How The Math Changes
The consolidation catalyst runs into a contract, not a balance sheet. The obvious thesis writes itself: Vireo is rolling up distressed US assets toward a pro forma 265 dispensaries, Curaleaf launched a hostile take-over bid for Aurora Cannabis on August 11, 2026, and Cronos is sitting on 827 million dollars of dry powder while everyone else scrapes for capital. So why has it not bought anything?
Part of the answer is in the Investor Rights Agreement, dated March 8, 2019, summarized in the FY2025 10-K. Altria Group bought 45 percent of Cronos that day for approximately 1.8 billion dollars. In exchange it received governance rights that are still live. While Altria holds at least 40 percent and the board is seven directors, Cronos must nominate four Altria designees, a board majority. And until Altria falls below 10 percent, Cronos may not, without Altria's prior written consent, merge or enter any similar business combination, acquire assets or businesses worth more than 100 million Canadian dollars, dispose of more than 60 million Canadian dollars of assets, or change its dividend policy.
Read that against the one acquisition Cronos has signed. CanAdelaar B.V., one of ten licensed producers in the Dutch Controlled Cannabis Supply Chain Experiment, agreed December 9, 2025 for 57.5 million euros up front, approximately 67.5 million US dollars, plus contingent consideration of 0.5 times normalized EBITDA in 2026 and 2027. At recent exchange rates that is roughly 90 to 95 million Canadian dollars, which sits under the 100 million dollar consent threshold. The company has already extended the closing deadline once, from June 9 to September 9, 2026, pending Dutch regulatory clearance, license confirmations and a Bibob background review.
The rescheduling catalyst runs into the same contract. A broad Schedule III determination is expected late 2026 or early 2027, and the natural question is which cash-rich operator walks into the United States first. Cronos, on the face of the agreement, cannot. The covenant bars it from engaging in the production, marketing, sale or distribution of cannabis in any jurisdiction, including the US, where the activity was prohibited by applicable law as of the date of the Investor Rights Agreement, subject to certain limitations. The test is frozen at March 2019. A change in US federal law in 2027 does not obviously release it. Altria's written consent does. The 10-Q's own forward-looking language keeps the door on the shelf, listing "our ability to identify and execute legally permissible opportunities to re-enter the U.S. market" among its risk assumptions.
So the cash is going to the shares instead. In the first half Cronos repurchased 12,253,870 common shares for 32.9 million dollars, an average of about 2.68 dollars a share, and retired all of them. Share count went from 381,592,969 to 370,726,047. On May 8, 2026 the board authorized a new program of up to 50.0 million dollars running to May 13, 2027. That is 6 percent of the cash pile per year. At that authorized pace it would take sixteen years to return the balance sheet.
The buyback has a second effect nobody put in a press release. Altria has not bought or sold a Cronos share since 2019; its 156.6 million share position is unchanged, which is exactly why 41.0 percent of the 381.6 million shares outstanding at year end matched its stake. Retire 10.9 million shares and hold Altria's position constant, and 41.0 percent becomes roughly 42.2 percent. Cronos is using its own cash to slowly walk its tobacco shareholder's stake back up, and away from the 40 percent cliff where the four-of-seven board right lapses. That arithmetic is ours, not the filing's, but the two inputs are both disclosed.
Worth stating plainly, because it is a common error: Altria's route to a bigger stake by purchase is gone. The warrant that would have taken it to roughly 52 percent was struck at 19.00 Canadian dollars and Altria abandoned it on December 16, 2022, ahead of its March 8, 2023 expiry, booking a 483 million dollar capital loss. Cronos closed at 3.81 Canadian dollars the day before. And Altria and Philip Morris are not in merger talks; those discussions were in 2019 and were terminated in January 2025.
Valuation: What It Is Worth If It Is A Normal Business
Strip the cash out and the operating business is nearly free. At 3.14 dollars and about 368 million shares, the market capitalization is roughly 1.157 billion dollars. Cronos has no debt. Subtract the 827.0 million dollars of cash, short-term investments and deposits and the enterprise value of the actual cannabis company is about 330 million dollars. That is 1.6 times annualized Q2 revenue of 212 million dollars, and about 6.3 times annualized Q2 Adjusted EBITDA of 52.4 million dollars.
The catch is which quarter you annualize. Q2 was a step change, and one quarter is not a run rate. Annualize the first half instead and Adjusted EBITDA is 36.3 million dollars, putting the operating business at about 9.1 times. Consumer packaged goods and health-and-wellness comparables trade in a 10 to 14 times EBITDA band. Applying that band gives an implied value range under stated assumptions:
| Scenario | Operating value | Plus cash 827.0M | Implied per share |
|---|---|---|---|
| Operations worth zero, cash only | 0 | 827.0M | 2.24 |
| H1 run rate (36.3M EBITDA) at 10x to 14x | 363M to 509M | 1.19B to 1.34B | 3.23 to 3.63 |
| Q2 run rate (52.4M EBITDA) at 10x to 14x | 524M to 733M | 1.35B to 1.56B | 3.67 to 4.23 |
| Israel duty imposed, Israel revenue lost | materially lower | closer to cash | below 3.00 |
Implied value under stated assumptions. Not a price target, not investment advice. Per-share figures use 368.4 million shares; the cash figure is the June 30, 2026 balance and nets no other liabilities. The 62.4 million dollars of total liabilities would reduce each row by about 0.17 per share.
Today's 3.14 dollars sits inside the H1 band and below the Q2 band. The market is roughly saying: the step change is real but not yet proven to repeat, and the cash is worth par. Note also what a floor of 2.24 dollars a share implies about Altria's position. Its 156.6 million shares are worth about 492 million dollars against the 1.8 billion dollars it paid in 2019.
Risks and Open Questions
The dated risk is Israel, and it landed one day before this filing. Israel was 15.0 million dollars of Q2 revenue, 28 percent of the total, growing 60 percent, and carrying no excise tax, which is the single largest contributor to the margin expansion this quarter. On June 29, 2026 Israel's Trade Levies Commissioner opened a new anti-dumping investigation into Canadian medical cannabis imports with a prima facie dumping margin of approximately 125 percent. It was terminated on procedural grounds July 28, a new complaint was filed July 30, and on August 5, 2026 the Commissioner notified Cronos of the initiation of a new investigation. The 10-Q was filed August 6. The prior round of this fight produced proposed duties of 369 percent and then 175 percent before a ministerial veto killed it in April 2025. Management said on the call that "Cronos does not engage in dumping" and that it will cooperate fully. The company states it cannot predict the outcome.
Beyond that: two customers are 44 percent of quarterly gross revenue. The reported bottom line swings on the Canadian dollar in both directions. The CanAdelaar deal has slipped once and is not closed. The 2019 restatement class action settlement of 10 million dollars received preliminary court approval on August 4, 2026 but one Ontario plaintiff intends to oppose it. Interest income, which is a third of pre-tax profit, falls with rates and is already declining. And the governance question cuts both ways: Altria's consent rights constrain Cronos, but Altria at 42 percent with four of seven board seats is also the reason nobody is going to buy Cronos without its blessing.
The Bottom Line
The framing that Cronos is a slowly depleting shell is wrong, and so is the framing that it is a coiled acquirer. The cash is not depleting: 831.8 million dollars to 827.0 million in six months, down 1 percent. The business is not a shell: record revenue, 54 percent gross margin, first positive operating income, 34.9 million dollars of operating cash flow. But it is not coiled either, because the constraint is not capital. It is a 2019 contract that requires a tobacco company's written consent for any acquisition over 100 million Canadian dollars, any merger, and any entry into a US cannabis market that was prohibited when the ink dried.
So what you own at 3.14 dollars is 2.23 dollars of Canadian guaranteed investment certificates, a real and suddenly accelerating cannabis business valued at about 330 million dollars, and a governance structure that decides what happens to both. Watch three things: whether Q2's 54 percent gross margin holds for a second quarter, whether the Israeli anti-dumping investigation produces a duty on 28 percent of revenue, and whether Cronos ever signs a deal that requires it to ask Altria for permission. That last one is the tell.
Every figure above was pulled from Cronos Group's SEC filings through the RoboSystems SEC Shared Repository: structured XBRL for every public company that files. Run your own: robosystems.ai/pricing. New customers get 50% off your first month with code CANNABIS50.
This is not investment advice. No price targets, no positions, no paid promotions.